In 2008, a new species for the French bee fauna was recorded in Allauch near Marseille: the giant resin bee, (Smith, 1853). This was the first European record of this species that is native to East Asia. To our knowledge, it is the first introduced bee species in Europe. Here, we provide an overview of the current distribution of in France and we describe the history of its range expansion. Besides our own observations, information was compiled from literature and Internet websites, and by contacting naturalist networks. We collected a total of 117 records ( × combinations) for the 2008-2016 period. The geographical range of has extended remarkably, now occupying a third of continental France, with the most northern and western records located 335 and 520 km from Allauch, respectively. Information on its phenology, feeding, and nesting behavior is also provided. We report several events of nest occupation or eviction of sp. and sp. individuals by . Our results show that is now well established in France. Given its capacity to adapt and rapidly expand its range, we recommend amplifying the monitoring of this species to better anticipate the changes in its geographical range and its potential impacts on native bees.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792562 | PMC |
| http://dx.doi.org/10.1002/ece3.3758 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Condylar Changes in Adult Patients with Unilateral Posterior Crossbite Following Microimplant-Assisted Rapid Palatal Expansion: A Retrospective CBCT Study.
J Stomatol Oral Maxillofac Surg
January 2025
Department of Orthodontics, Hubei-MOST KLOS & KLOBM, School & Hospital of Stomatology, Wuhan University, Wuhan, China.. Electronic address:
Objectives: This study aims to assess the alterations in condylar positioning in adult skeletal Class I patients with unilateral posterior crossbite after microimplant-assisted rapid palatal expansion (MARPE) treatment.
Methods: This retrospective study involving 30 participants (10 males, 20 females) average age 22.9 ± 4.
Opioid use disorder prevalence in 57 New York counties from 2017 to 2019: A Bayesian evidence synthesis.
Drug Alcohol Depend
January 2025
University of Miami Miller School of Medicine, Department of Public Health Sciences, United States.
Introduction: Prevalence estimates of opioid use disorder (OUD) at local levels are critical for public health planning and surveillance, yet largely unavailable across the US especially at the local county level.
Methods: We used a Bayesian evidence synthesis approach to estimate the prevalence of OUD for 57 counties across New York State for 2017-2019 and compare rates of OUD across counties as well as assess the extent of undiagnosed OUD. We developed a generative model to assess conditional probabilistic relations between different subgroups of the OUD population defined by diagnosis, treatment, and overdose fatality.
From the Atlantic-Mediterranean to the Western Pacific: First record of potentially harmful invasive gilthead sea bream (Sparus aurata) in the Northern Taiwan.
Mar Pollut Bull
January 2025
Institute of Fisheries Science, College of Life Science, National Taiwan University, Taipei, Taiwan. Electronic address:
In this study, a pair of matured specimens of gilthead sea bream (Sparus aurata Linnaeus, 1758) were collected at a depth of approximately 20 m near Keelung Port, northern Taiwan (25°11'32″N, 121°47'8″E), on November 23, 2024. The specimens were identified and confirmed as S. aurata through both morphological and molecular analyses.
View Article and Find Full Text PDFProton therapy of lung cancer patients - Treatment strategies and clinical experience from a medical physicist's perspective.
Phys Med
January 2025
Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address:
Purpose: Proton therapy of moving targets is considered a challenge. At Maastro, we started treating lung cancer patients with proton therapy in October 2019. In this work, we summarise the developed treatment strategies and gained clinical experience from a physics point of view.
View Article and Find Full Text PDFArticle Synopsis
- FT596 is a novel cancer therapy using iPSC-derived CAR NK cells targeting CD19, designed to assess its safe dosage and effectiveness alone and with rituximab in patients with B-cell lymphoma.
- This phase 1 trial involved patients with relapsed or refractory B-cell lymphoma, administering FT596 after chemotherapy, with separate regimens for those receiving rituximab and those who did not.
- The study measured potential side effects while determining the optimal dose of FT596 and allowed modifications to the treatment based on patient tolerance and response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!